AHA announces late-breaking science lineup to be presented during the virtual meeting
Click Here to Manage Email Alerts
The American Heart Association Scientific Sessions will be a fully virtual event held Nov. 13-15, 2021, and will feature seven late-breaking science sessions over 3 days.
The late-breakers include new data from the landmark EMPEROR-Preserved trial of empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) in patients with HF with preserved ejection fraction; the PREPARE-IT 2 trial of icosapent ethyl (Vascepa, Amarin) as a treatment in outpatients with COVID-19; and the Fitbit Heart Study, which will provide data on detection of atrial fibrillation in patients using the Fitbit wearable device.
The AHA announced the following late-breaking science lineup for the annual meeting:
Late-Breaking Science 1: Valves, Veins and New Viewpoints in Cardiothoracic Surgery
- Aortic Valve Replacement Versus Watchful Waiting in Asymptomatic Severe Aortic Stenosis: The AVATAR Trial
- Evaluating the Benefit of Concomitant Tricuspid Repair During Mitral Valve Surgery
- A Randomized Study of Early Versus Standard Coronary Artery Bypass Surgery Among Patients Presenting with Acute Coronary Syndromes Treated with Ticagrelor (RAPID CABG)
- Efficacy and Safety of an External Support Device for Saphenous Vein Coronary Bypass Grafts: The VEST Trial
Late-Breaking Science 2: Hypertension: Local, Global and Pandemic Impacts
- A Remotely Delivered Hypertension and Lipid Program in 10,000 Patients Across a Diverse Health Care Network
- Disruption in Blood Pressure Control with the COVID-19 Pandemic: A Study of 24 U.S. Health Systems in the PCORnet Blood Pressure Control Laboratory (BP Track)
- A Cluster Randomized Trial of a Village Doctor-Led Intervention on Blood Pressure Control: China Rural Hypertension Control Project (CRHCP)
Late-Breaking Science 3: Prevention to Intervention in Atrial Arrhythmias
- The Coffee and Real-Time Atrial and Ventricular Ectopy (CRAVE) Trial
- Dabigatran Versus Warfarin on Cognitive Outcomes in Nonvalvular Atrial Fibrillation: Results of the GIRAF Trial
- Posterior Left Pericardiotomy Reduces Postoperative Atrial Fibrillation After Cardiac Surgery (PALACS)
- Outcomes of Adjunctive Left Atrial Appendage Ligation Utilizing the LARIAT Compared to Pulmonary Vein Antral Isolation Alone: The AMAZE Trial
Late-Breaking Science 4: Information Overload? Striving to Improve Care Delivery Through Digital Health and Automated Data
- Risk Evaluation and its Impact on Clinical Decision-Making and Outcomes in Heart Failure: The REVeAL-HF Trial
- Detection of Atrial Fibrillation in a Large Population Using Wearable Devices: The Fitbit Heart Study
- Testing Individualized Triggers of Atrial Fibrillation: A Randomized Controlled Trial (I-STOP-AFib)
Late-Breaking Science 5: Building on the Foundations of Treatment: Advances in Heart Failure Therapy
- Heart Failure With a Preserved Ejection Fraction 50% - Results From the EMPEROR-Preserved Clinical Trial
- The Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF) Clinical Trial
- Efficacy and Safety of Empagliflozin in Hospitalized Heart Failure Patients: Main Results From the EMPULSE Trial
- Randomized Trial of Targeted Transendocardial Delivery of Mesenchymal Precursor Cells in High-Risk Chronic Heart Failure Patients with Reduced Ejection Fraction (DREAM-HF)
Late-Breaking Science 6: Fish Oil, Cocoa and Cholesterol: Recipes for CVD Prevention?
- Icosapent Ethyl Versus Placebo in Outpatients with Covid-19: The Main Results of PREPARE-IT 2
- Primary Findings from the Cocoa Supplement and Multivitamin Outcomes Study (COSMOS) on the Prevention of Cardiovascular Disease
- The Clinical Safety, Pharmacokinetics and LDL-Cholesterol Lowering Efficacy of MK-0616, an Oral PCSK9 Inhibitor
Late-Breaking Science 7: New Drugs and New Drug Indications in Cardiovascular Disease
- Effects of Aspirin on Dementia and Cognitive Impairment in the ASCEND Trial
- P2y12 Inhibitors in Noncritically Ill Hospitalized Patients with Covid-19 (ACTIV-4A)
- Effect Of Bentracimab on Platelet Inhibition and Hemostasis in Ticagrelor Patients with Uncontrolled Hemorrhage or Requiring Urgent Surgery in the REVERSE-IT
- Milvexian for Prevention of Venous Thromboembolism After Elective Knee Arthroplasty: The AXIOMATIC-TKR Study
Click Here to Manage Email Alerts